PMID- 19629070
OWN - NLM
STAT- MEDLINE
DCOM- 20090811
LR  - 20220413
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Linking)
VI  - 9
IP  - 8
DP  - 2009 Aug
TI  - Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
PG  - 550-62
LID - 10.1038/nrc2664 [doi]
AB  - There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway 
      is vital to the growth and survival of cancer cells. Inhibitors targeting this 
      pathway are entering the clinic at a rapid pace. In this Review, the therapeutic 
      potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is 
      discussed. I focus on the advantages and drawbacks of different treatment 
      strategies for targeting this pathway, the cancers that might respond best to 
      these therapies and the challenges and limitations that confront their clinical 
      development.
FAU - Engelman, Jeffrey A
AU  - Engelman JA
AD  - Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA. 
      jengelman@partners.org
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy/*etiology/pathology
MH  - Phosphatidylinositol 3-Kinases/*physiology
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Protein Kinases/physiology
MH  - Proto-Oncogene Proteins c-akt/*physiology
MH  - Signal Transduction/drug effects/*physiology
MH  - TOR Serine-Threonine Kinases
RF  - 159
EDAT- 2009/07/25 09:00
MHDA- 2009/08/12 09:00
CRDT- 2009/07/25 09:00
PHST- 2009/07/25 09:00 [entrez]
PHST- 2009/07/25 09:00 [pubmed]
PHST- 2009/08/12 09:00 [medline]
AID - nrc2664 [pii]
AID - 10.1038/nrc2664 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.